Attero NDC 87143-100

NDC codes

FDA NDC Directory

Product NDC (as listed)87143-100Labeler and product segments. Claims need a package NDC.

Product NDC at billing width87143-0100Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
87143-100-60	87143010060	1 BOTTLE, PLASTIC in 1 CARTON (87143-100-60) / 60 g in 1 BOTTLE, PLASTICMarketed from Jun 1, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Attero
Generic name (nonproprietary): calcipotriene and betamethasone dipropionate
Active ingredients: Calcipotriene — .05 mg/gBetamethasone dipropionate — .5 mg/g
Dosage form: Solution
Route: Topical
Labeler: Perfero Pharma, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210765
Marketing start: Jun 1, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)Vitamin D (Chemical structure)
Identifiers: Product ID 87143-100_262aa95f-9145-43a2-b144-41dd68fa6212SPL ID 262aa95f-9145-43a2-b144-41dd68fa6212SPL set ID 328148a1-f32e-47a8-99ec-1614c291a450UNII 143NQ3779B, 826Y60901U
Pharmacologic class: Corticosteroid; Vitamin D Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N487143010060 followed by a unit qualifier and the quantity

Package 87143-0100-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 18, 2026.

Indications (excerpt from the label)

ATTERO™ Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp in patients 12 years and older and plaque psoriasis of the scalp and body in patients 18 years and older. Additional pediatric use information is approved for LEO Pharma A/S's Taclonex ® (calcipotriene and betamethasone dipropionate) Topical Suspension. However, due to LEO Pharma A/S's marketing exclusivity rights, this drug product is not labeled with that information. ATTERO™ Topical Suspension is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis of the scalp in patients 12 years and ol…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210765

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210765
Product	Strength	Form · route	Labeler	Product NDC
calcipotriene and betamethasone dipropionate	Betamethasone dipropionate .5 mg/g; Calcipotriene 50 ug/g	SuspensionTopical	Cosette Pharmaceuticals, Inc.	0713-0848